Evidence map›Paper›PMID 21124930›Full record

ArticlePloS one2010

IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Mary Zimmerman, Dafeng Yang, Xiaolin Hu, Feiyan Liu, Nagendra Singh, Darren Browning, Vadivel Ganapathy, Phillip Chandler, Divaker Choubey, Scott I Abrams and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Hyperprogression: A novel response pattern under immunotherapy.Clinical and translational medicine · 2020
    Review
  11. Article
  12. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.International journal of molecular sciences · 2018
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Circulating survivin levels in healthy and asthmatic pregnancy.Reproductive biology and endocrinology : RB&E · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mary ZimmermanDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, USA.
Dafeng Yang
Xiaolin Hu
Feiyan Liu
Nagendra Singh
Darren Browning
Vadivel Ganapathy
Phillip Chandler
Divaker Choubey
Scott I Abrams
Kebin Liu
Augusta University · USAugusta University Health · USRoswell Park Comprehensive Cancer Center · USUniversity of Cincinnati · US

Funding

Role of IRF8 in Tumor Rejection and SuppressionR01CA133085 · NCI · AUGUSTA UNIVERSITY · PI LIU, KEBIN · 2008 to 2019
$2.9M
NCI NIH HHS CA133085NCI NIH HHS R01 CA133085
6 · The paper itself

Abstract

backgroundA common procedure in human cytotoxic T lymphocyte (CTL) adoptive transfer immunotherapy is to expand tumor-specific CTLs ex vivo using CD3 mAb prior to transfer. One of the major obstacles of CTL adoptive immunotherapy is a lack of CTL persistence in the tumor-bearing host after transfer. The aim of this study is to elucidate the molecular mechanisms underlying the effects of stimulation conditions on proliferation and survival of tumor-specific CTLs. METHODOLOGY/PRINCIPAL

findingsTumor-specific CTLs were stimulated with either CD3 mAb or cognate Ag and analyzed for their proliferation and survival ex vivo and persistence in tumor-bearing mice. Although both Ag and CD3 mAb effectively induced the cytotoxic effecter molecules of the CTLs, we observed that Ag stimulation is essential for sustained CTL proliferation and survival. Further analysis revealed that Ag stimulation leads to greater proliferation rates and less apoptosis than CD3 mAb stimulation. Re-stimulation of the CD3 mAb-stimulated CTLs with Ag resulted in restored CTL proliferative potential, suggesting that CD3 mAb-induced loss of proliferative potential is reversible. Using DNA microarray technology, we identified that survivin and ifi202, two genes with known functions in T cell apoptosis and proliferation, are differentially induced between Ag- and CD3 mAb-stimulated CTLs. Analysis of the IFN-γ signaling pathway activation revealed that Ag stimulation resulted in rapid phosphorylation of STAT1 (pSTAT1), whereas CD3 mAb stimulation failed to activate STAT1. Chromatin immunoprecipitation revealed that pSTAT1 is associated with the promoters of both survivin and ifi202 in T cells and electrophoresis mobility shift assay indicated that pSTAT1 directly binds to the gamma activation sequence element in the survivin and ifi202 promoters. Finally, silencing ifi202 expression significantly decreased T cell proliferation. CONCLUSIONS/SIGNIFICANCE: Our findings delineate a new role of the IFN-γ signaling pathway in regulating T cell proliferation and apoptosis through upregulating survivin and ifi202 expression.

Indexed as

AnimalsAntibodies, MonoclonalApoptosisBlotting, WesternCD3 ComplexCell Line, TumorCell ProliferationCell SurvivalFemaleGene Expression ProfilingImmunotherapy, AdoptiveInhibitor of Apoptosis ProteinsInterferon-gammaInterferon gamma ReceptorIntracellular Signaling Peptides and ProteinsMiceAntibodies, MonoclonalBirc5 protein, mouseCD3 ComplexIfi202b protein, mouseInhibitor of Apoptosis ProteinsInterferon-gammaInterferon gamma ReceptorIntracellular Signaling Peptides and ProteinsReceptors, InterferonRepressor ProteinsStat1 protein, mouseSTAT1 Transcription FactorSurvivin

Identifiers

PMID21124930
PMCPMC2989915
OpenAlexW2084654470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.